ADVERSE REACTIONS TO BENZODIAZEPINE TRANQUILIZERS, IN PARTICULAR IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME

Download full text PDF
Issue: 
9
Year: 
2017

E. Ivanova (1, 2); D. Ivashchenko (3); L. Savchenko (4), E. Bryun (4, 5), D. Sychev (4), 1-Young Scientists’ School of Pharmacogenetics, Pharmacogenomics, and Personalized Medicine, Russian Medical Academy of Continuing Education, Moscow 2-Mental Health Research Center, Moscow 3-Sector for Applied Problems of Personalized Medicine, Research Center, Russian Medical Academy of Continuing Education, Moscow 4-Russian Medical Academy of Continuing Education, Moscow 5-Moscow Research and Practical Center for Narcology, Moscow Healthcare Department

The paper describes the mechanism of action, classification, effects, specific and non-specific adverse reactions to benzodiazepine tranquilizers (BT). It considers the adverse reactions developing in the treatment of patients with alcohol withdrawal syndrome. The adverse reactions to BT develop in a significant proportion of patients; they are mainly associated with the sedative effects of the drugs and dose-dependent. In this connection, it is relevant to investigate the risk factors and biomarkers, which can predict the development of adverse reactions.
Keywords: 
pharmacology
benzodiazepines
alcoholism
alcohol withdrawal syndrome
safety
adverse reactions

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ladyzhenskij M.Ja., Gorodnichev A.V., Kostjukova E.G. Benzodiazepinovye anksiolitiki: vostrebovany li oni segodnja? // Sovremennaja terapija psihicheskih rasstrojstv. – 2014; 2: 20–5.
  2. Osadshij Ju.Ju., Voblenko R.A., Archakov D.S. i dr. Mesto benzodiazepinov v sovremennoj terapii psihicheskih rasstrojstv (obzor dokazatel'nyh issledovanij) // Sovremennaja terapija psihicheskih rasstrojstv. – 2016; 1: 2–10.
  3. Olsen R., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update // Pharmacol. Rev. – 2008; 60 (3): 243–60.
  4. Saari T., Uusi-Oukari M., Ahonen, J. et al. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology // Pharmacol. Rev. – 2011; 63 (1): 243–67.
  5. Belelli D. Extrasynaptic GABAA Receptors of Thalamocortical Neurons: A Molecular Target for Hypnotics // J. Neurosci. – 2005; 25 (50): 11513–20.
  6. Ernst M., Brauchart D., Boresch S. et al. Comparative modeling of GABAA receptors: Limits, insights, future developments // Neuroscience. – 2003; 119 (4): 933–43.
  7. Greenblatt D., Shader R., Divoll M. et al. Benzodiazepines: a summary of pharmacokinetic properties // Br. J. Clin. Pharmacol. – 1981; 11 (Suppl. 1): 11–6.
  8. Bird R., Makela E. Alcohol withdrawal: What is the benzodiazepine of choice? // Ann. Pharmacother. – 1994; 28 (1): 67–71.
  9. Kurko T., Saastamoinen L., Tähkäpää S. et al. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies // Eur. Psychiatry. – 2015; 30 (8): 1037–47.
  10. Martins A., Giordani F., Rozenfeld S. Adverse drug events among adult inpatients: a meta-analysis of observational studies // J. Clin. Pharm. Ther. – 2014; 39 (6): 609–20.
  11. Jick H. Drugs – remarkably nontoxic // N. Engl. J. Med. – 1974; 291 (16): 824–8.
  12. Resar R., Rozich J., Simmonds T. et al. A trigger tool to identify adverse events in the intensive care unit // Jt. Comm. J. Qual. Patient. Saf. – 2006; 32 (10): 585–90.
  13. Nazarenko G.I., Klejmenova E.B., Otdelenov V.A. i dr. Ispol'zovanie triggerov nezhelatel'nyh sobytij dlja vyjavlenija pobochnyh reaktsij pri primenenii lekarstvennyh sredstv v statsionare // Klin. farmakol. i ter. – 2015; 4 (24): 55–62.
  14. Busto U., Naranjo C., Sellers E. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions // Br. J. Clin. Pharmacol. – 1982; 13 (2): 223–7.
  15. Gallagher R., Kirkham J., Mason J. et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool // PLoS One. – 2011; 6 (12): e28096.
  16. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound // J. Clin. Psychiatry. – 2004; 65 (Suppl. 5): 7–12.
  17. Pariente A., Dartigues J.-F., Benichou J. et al. Benzodiazepines and injurious falls in community dwelling elders // Drugs Aging. – 2008; 25 (1): 61–70.
  18. Uzun S., Kozumplik O., Jakovljević M. et al. Side effects of treatment with benzodiazepines // Psychiatr. Danub. – 2010; 22 (1): 90–3.
  19. Arbanas G., Arbanas D., Dujam K. Adverse effects of benzodiazepines in psychiatric outpatients // Psychiatr. Danub. – 2009; 21 (1): 103–7.
  20. Nott D., Chandrasekar R., Enabi L. et al. Intra-arterial injection of temazepam in drug abusers // Eur. J. Vasc. Surg. – 1993; 7 (1): 87–9.
  21. Ruben S., Morrison C. Temazepam misuse in a group of injecting drug users // Br. J Addict. – 1992; 87 (10): 1387–92.
  22. De Witte P., Pinto E., Ansseau M. et al. Alcohol and withdrawal: From animal research to clinical issues // Neurosci. Biobehav. Rev. – 2003; 27 (3): 189–97.
  23. Sachdeva A., Choudhary M., Chandra M. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond // J. Clin. Diagn. Res. – 2015; 9 (9): VE01–VE07.
  24. Rubio G., López-Muñoz F., Ponce G. et al. Zonisamide versus diazepam in the treatment of alcohol withdrawal syndrome // Pharmacopsychiatry. – 2010; 43 (7): 257–62.
  25. Addolorato G., Leggio L., Abenavoli L. et al. Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam // Am. J. Med. – 2006; 119 (3): 276.e13–276.e18.
  26. Lucht M., Kuehn K., Armbruster J. et al. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: A controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam // Alcohol and Alcoholism. – 2003; 38 (2): 168–75.
  27. Martinotti G., di Nicola M., Frustaci A. et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: A multi-centre, randomized, single-blind comparison trial // Addiction. – 2010; 105 (2): 288–99.
  28. Myrick H., Malcolm R., Randall P. et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal // Alcohol. Clin. Exp. Res. – 2009; 33 (9): 1582–8.
  29. Kumar C., Andrade C., Murthy P. A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal // J. Stud. Alcohol. Drugs. – 2009; 70 (3): 467–74.
  30. Ramanujam R., Lakshminarayana P., Gopalrao S. et al. A comparative study of the clinical efficacy and safety of Lorazepam and chlordiazepoxide in alcohol dependence syndrome // J. Clin. Diagn. Res. – 2015; 9 (3): FC10–FC13.
  31. Bonnet U., Lensing M., Specka M., et al. Comparison of two oral symptom-triggered pharmacological inpatient treatments of acute alcohol withdrawal: Clomethiazole vs. Clonazepam // Alcohol and Alcoholism. – 2011; 46 (1): 68–73.
  32. Crispo A., Daley M., Pepin J. et al. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: Dexmedetomidine versus benzodiazepines // Pharmacotherapy. – 2014; 34 (9): 910–7.
  33. Sen S., Grgurich P., Tulolo A. et al. Evaluation of a Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill // Ann. Pharmacother. – 2016; 51 (2): 101–10.
  34. Wong A., Benedict N., Lohr B. et al. Management of benzodiazepine-resistant alcohol withdrawal across a healthcare system: Benzodiazepine dose-escalation with or without propofol // Drug. Alcohol. Depend. – 2015; 154: 296–9.
  35. Park H., Satoh H., Miki A. et al. Medications associated with falls in older people: systematic review of publications from a recent 5-year period // Eur. J. Clin. Pharmacol. – 2015; 71 (12): 1429–40.
  36. Chang C.-M., Chen M.-J., Tsai C.-Y. et al. Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study // Int. J. Geriatr. Psychiatry. – 2011; 26 (6): 602–7.
  37. Sgadari A., Lapane K., Mor V. et al. Oxidative and nonoxidative benzodiazepines and the risk of femur fracture. The Systematic Assessment of Geriatric Drug Use Via Epidemiology Study Group // J. Clin. Psychopharmacol. – 2000; 20 (2): 234–9.